Karyopharm Therapeutics (KPTI) Asset Utilization Ratio (2013 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Asset Utilization Ratio came in at 1.43 in Q4 2025, up 73.92% YoY from 0.82 in Q4 2024, and up 0.71% on a QoQ basis from 1.42 in Q3 2025.
Karyopharm Therapeutics (KPTI) Asset Utilization Ratio (2013 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 13 years of Asset Utilization Ratio data on file, last reported at 1.43 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 73.92% year-over-year to 1.43 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.43 (up 73.92% YoY) and the FY2025 annual result came in at 1.07, up 49.24% from the prior year.
- Asset Utilization Ratio climbed to 1.43 in Q4 2025, from 1.42 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 1.43 in Q4 2025 to a low of 0.36 in Q2 2021.
- A 5-year average of 0.75 and a median of 0.72 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 150.56% — and 2023, when it plunged 49.83%.
- Tracing KPTI's Asset Utilization Ratio over 5 years: stood at 0.75 in 2021, then slipped by 28.95% to 0.53 in 2022, then grew by 7.36% to 0.57 in 2023, then jumped by 43.44% to 0.82 in 2024, then jumped by 73.92% to 1.43 in 2025.
- The last three Asset Utilization Ratio figures came in at 1.43 (Q4 2025), 1.42 (Q3 2025), and 1.18 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.06 |
| Dec 31, 2025 | 1.43 |
| Sep 30, 2025 | 1.42 |
| Jun 30, 2025 | 1.18 |
| Mar 31, 2025 | 0.97 |
| Dec 31, 2024 | 0.82 |
| Sep 30, 2024 | 0.74 |
| Jun 30, 2024 | 0.70 |
| Mar 31, 2024 | 0.63 |
| Dec 31, 2023 | 0.57 |
| Sep 30, 2023 | 0.51 |
| Jun 30, 2023 | 0.47 |
| Mar 31, 2023 | 0.43 |
| Dec 31, 2022 | 0.53 |
| Sep 30, 2022 | 1.02 |
| Jun 30, 2022 | 0.91 |
| Mar 31, 2022 | 0.78 |
| Dec 31, 2021 | 0.75 |
| Sep 30, 2021 | 0.44 |
| Jun 30, 2021 | 0.36 |